Welcome to the CJU website » LOG IN


Prognostic markers for urologic cancers
Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
Feb  2016 (Vol.  23, Issue  1, Pages( 8155 - 8155)
PMID: 26892056


Text-Size + 

  • Improved prediction of disease related oncologic outcomes is essential for improved patient counseling prior to surgery. The concept of chronic inflammatory states and association with cancer recurrence and survival is a growing area of interest. Indeed a number of studies highlight the potential prognostic benefit across different malignancies. Nonetheless, the impact of neutrophil:lymphocyte ratio (NLR) is variable and certainly not uniform. As highlighted by Bazzi et al (as well as others), NLR had no significant prognostic benefit for recurrence-free and cancer-specific survival for clear cell renal cell carcinoma (ccRCC).1 One wonders if some of these observations are a function of a heterogenous cohort of ccRCC cases ranging from T1a toT4 tumors of various Fuhrman grades. Indeed, a focus on more biologically aggressive ccRCC at higher risk of recurrence and mortality may demonstrate a greater degree of association. Furthermore, whilst these authors noted an association of NLR with overall survival, there was no incremental benefit over a base model constructed from clinical measures of frailty. These observations highlight that accurate pre-surgical notation of baseline clinical morbidities may be invaluable when assessing overall prognosis for urologic oncology patients. In that regard, more refined scales such as ECOG performance status, Charlson-Romano index, or an amalgam to create a Frailty Index Score may be superior to the ASA score alone.